title: The primary in vitro antitumor screening of "half-mustard type" phenothiazines.
abstract: The antitumor effects of "half-mustard type" phenothiazines were studied on 57 different tumor cell lines, including leukemias, non-small lung cancer, colon, central nervous system, ovarian, renal, breast, and prostate cancer, as well as melanoma cell cultures. Alkyl-urea derivatives of phenothiazines displayed in vitro antitumor activity. The phenothiazine phthalimido derivatives (1-6) were not active on the majority of cancer cell cultures. In contrast, propylureas (9, 11) were active against some leukemia cell types. Only two compounds with the butylene [(CH2)4] linker (10, 12) were active against non-small lung cancer cells. Compounds containing the propylene linker were less effective. On colon cancer lines, tumor cells from the central nervous system and on melanoma cells the same compounds were effective, however, having substituents at the 2-position of phenothiazine seems to be important. Surprisingly, the majority of ovarian cancer cell lines (except one type, IGROVI) and five of eight renal cancer lines were not sensitive to these phenothiazine derivatives. The two butylene linked phenothiazine ureas (10, 12) had moderate antiproliferative action on two renal cancer cell lines. The prostate cancer and some breast cancer cell lines were not sensitive. Nevertheless some breast cancer cell lines were apparently sensitive to CF3-substituted phenothiazine alkylureas. On the basis of these experiments one may postulate that in the case of insensitive cells an mdr-gene encoded multidrug resistance efflux pump is responsible for the resistance. The selectivity or organ cell specificity of the effective phenothiazines will be targeted for improvement in further studies, in order to avoid the general cytotoxic effects of "half mustard type" phenothiazines.
authors.affiliation: SCRIPTGEN Pharmaceuticals, Inc., Medford, MA 02155, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Wuonola
authors.forename: M G
authors.initials: MG
authors.lastname: Palfreyman
authors.forename: N
authors.initials: N
authors.lastname: Motohashi
authors.forename: M
authors.initials: M
authors.lastname: Kawase
authors.forename: S
authors.initials: S
authors.lastname: Gabay
authors.forename: J
authors.initials: J
authors.lastname: Nacsa
authors.forename: J
authors.initials: J
authors.lastname: Molnár
mesh_terms: D000970:Antineoplastic Agents; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010640:Phenothiazines / Q000494:pharmacology*; D010797:Phthalimides / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D010640:Phenothiazines; D010797:Phthalimides; D014508:Urea